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Abstract
Introduction: Subacute sclerosing panencephalitis (SSPE) is a late, rare and usually fatal complication of measles infection.
Although a very high incidence of SSPE in Papua New Guinea (PNG) was first recognized 20 years ago, estimated measles
vaccine coverage has remained at #70% since and a large measles epidemic occurred in 2002. We report a series of 22 SSPE
cases presenting between November 2007 and July 2009 in Madang Province, PNG, including localized clusters with the
highest ever reported annual incidence.
Methodology/Principal Findings: As part of a prospective observational study of severe childhood illness at Modilon
Hospital, the provincial referral center, children presenting with evidence of meningo-encephalitis were assessed in detail
including lumbar puncture in most cases. A diagnosis of SSPE was based on clinical features and presence of measles-
specific IgG in cerebrospinal fluid and/or plasma. The estimated annual SSPE incidence in Madang province was 54/million
population aged ,20 years, but four sub-districts had an incidence .100/million/year. The distribution of year of birth of
the 22 children with SSPE closely matched the reported annual measles incidence in PNG, including a peak in 2002.
Conclusions/Significance: SSPE follows measles infections in very young PNG children. Because PNG children have known
low seroconversion rates to the first measles vaccine given at 6 months of age, efforts such as supplementary measles
immunisation programs should continue in order to reduce the pool of non-immune people surrounding the youngest and
most vulnerable members of PNG communities.
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Introduction
Despite a declining incidence in developed countries, acute
measles infection is still responsible for an estimated 164,000
deaths/year and is therefore a major vaccine-preventable cause of
death worldwide [1,2]. Subacute sclerosing panencephalitis (SSPE)
is a rare but usually fatal late complication which presents 3–10
years after the acute infection. SSPE is a distinctive clinical entity
characterized by behavioural changes and myoclonic jerks,
followed by motor dysfunction and profound global cognitive
impairment, and then death within a few years of presentation in
most cases. The diagnosis is made by the presence of characteristic
clinical signs and, if available, electroencephalographic (EEG)
findings in conjunction with elevated measles-specific antibodies in
serum and cerebrospinal fluid (CSF) [3].
The incidence of SSPE in most countries is ,5 per million
population ,20 years of age, although this figure can be higher in
the developing world where vaccination programs are not fully
established [4]. The first reports of an unusually high incidence in
Papua New Guinea (PNG) were published in the early 1990’s [5],
with rates between 1988 and 1999 that varied from 13 [5] to 98
[6] per million population ,20 years of age. However, these data
need to be interpreted against fluctuations in the incidence of
acute measles infection over the preceding decade, and should take
into account background vaccination coverage and the possibility
that localized clusters may contribute disproportionately to overall
incidence rates estimated at provincial or country level. In
addition, published PNG data to date have come from highland
areas which may not be representative of the country as a whole.
We report a series of children presenting to a coastal PNG
provincial referral hospital with clinical and laboratory features
typical of SSPE. Using available local demographic data, as well as
retrospective vaccination and disease surveillance, we have
estimated the annual incidence of SSPE in Madang Province
www.plosntds.org 1 January 2011 | Volume 5 | Issue 1 | e932and interpreted this figure in relation to prior national measles
vaccination coverage and acute measles incidence, as well as the
regional distribution of cases.
Methods
Ethics statement
Approval for the study was provided by the PNG Institute of
Medical Research Institutional Review Board and the Medical
Research Advisory Committee of the PNG Health Department.
Written informed consent for participation was obtained from
parent(s)/guardian(s). The risks and benefits of lumbar puncture
(LP) were explained to parent(s)/guardian(s) by the attending ward
pediatrician who carried out the procedure with regard for
conventional indications (suspicion of meningitis, subarachnoid
hemorrhage or central nervous system disease) and contraindica-
tions (such as increased intracranial pressure or coagulopathy) [7].
Study site and patients
Madang Province on the North Coast of PNG has an estimated
population of approximately 450,000 people, 54% of whom are
,20 years old [8]. Modilon Hospital is the provincial referral
hospital and the only health care facility in the province that offers
diagnostic and treatment facilities for severely ill patients. A
longitudinal detailed observational study of severe illness in all
children aged 6 months to 10 years was started at Modilon
Hospital at the end of 2006. Prior to this initiative, documentation
of cases was insufficient to allow epidemiologic analyses of specific
diseases. In November 2007, the first child with symptoms and
signs of SSPE was admitted to the present study. There was a
subsequent increase in the numbers of similar cases before a
decline after 12 months. Data collection was continued until July
2009, at which time relatively few such cases were being admitted.
National and local measles epidemiology
Measles immunization was started in PNG in 1982. A modified
two-dose schedule at six and nine months of age was used with the
aim of providing partial coverage for young infants at high risk of
pneumonia and SSPE [9]. However, subsequent available national
data indicate that coverage has remained low (see Figure 1). In a
recent study of 2007 data, for example, 58% of eligible children
received the first dose and 47% the second dose [10]. Cyclical
measles epidemics have continued to occur, the last in 2002 (see
Figure 2) [11,12,13]. Supplementary immunisation activities (SIA)
for children aged 6 months to 7 years have been deployed since
2004, with a reported coverage of 79% in 2008 [13].
The measles vaccine coverage recorded in the health diaries of
children in Madang Province is similar to that reported elsewhere
in PNG, with 41% of children ,10 years of age surveyed at two
sites within a 20 km radius of Madang town between September
2007 and June 2008 having received at least one dose [10].
Nevertheless, an increasing seroprevalence with age (60% and
79% for children 1–4 years and 5–9 years old, respectively) may
indicate that wild measles virus remains prevalent in the
community [10] and that there is under-reporting of cases as
found in other epidemiologic settings [14,15].
Clinical assessment
After recruitment, a standardized case report form was
completed detailing demographic information, medical history
and history of the current illness. Vaccination history was
identified from the health record book held by the parent(s)/
guardian(s) of each child where this was available. Since there is no
local or central vaccination register, it was assumed that children
without such documentation were unvaccinated. Standardized
physical assessment included nutritional status assessed by
calculating a weight-for-height Z-score [16], with a value ,2
considered to indicate malnutrition. We defined severe illness as
the presence of one or more of the following features: i) impaired
consciousness or coma (Blantyre Coma Score (BCS) ,5 [17]), ii)
prostration (inability to sit or stand unaided), iii) multiple seizures,
iv) hyperlactatemia (blood lactate .5 mmol/L), v) severe anemia
(hemoglobin ,50 g/L), vi) dark urine, vii) hypoglycemia (blood
glucose ,2.2 mmol/L), viii) jaundice, or xi) respiratory distress.
These criteria are consistent with the World Health Organisation
definition for severe malaria [18].
Children with clinical evidence of SSPE, including myoclonic
jerks, behavioural changes, and/or speech and motor deficits,
underwent detailed neurologic examination by study clinicians
(LM, ML). Level of consciousness was graded according to
Blantyre Coma Score [17]. Upper motor neuron signs were
considered to be present if the child had i) extensor plantar
responses, ii) increased muscle tone of either upper or lower limbs,
iii) sustained clonus, iv) hyperreflexia, and/or v) pyramidal tract
muscle weakness of either upper or lower limbs. In children whose
parents/guardians provided informed consent and who had no
contraindications, LP was performed. All children were examined
daily until discharge at which time a basic assessment of
performance status was made. Moderate disability was defined
as that requiring considerable assistance with self-care and severe
disability as that requiring special assistance with all self-care,
categories that are consistent with Karnovsky’s performance scores
of 50% and ,50%, respectively [19].
Laboratory tests
CSF was examined macroscopically for turbidity, blood staining
and clots. We used the Neubauer Improved counting chamber
(BoeCo, Germany) to obtain total and differential CSF white cell
counts (WCC). Semi-quantitative measures of CSF glucose and
protein were performed using dipsticks (Acon Laboratories, San
Diego, USA). Specific measles IgG in CSF and serum was
measured using a standard indirect immunofluorescence antibody
assay (IFA). Serial two-fold dilutions of patient samples were added
to separate wells of glass slides to which were fixed measles virus-
infected Vero cells. After incubation and washing, anti-human IgG
fluorescein isothiocyanate conjugate was then added and,
following further incubation and washing, slides were examined
Author Summary
Subacute sclerosing panencephalitis (SSPE) is a disabling
and usually fatal brain disorder that typically occurs 3–10
years after acute measles infection. Papua New Guinea
(PNG) has particularly high rates of SSPE. We report 22
cases of PNG children presenting to the provincial referral
hospital in Madang Province who probably contracted
acute measles when ,12 months of age during a national
epidemic in 2002 and who developed SSPE 5–7 years later.
Based on these cases, the estimated annual SSPE incidence
in Madang province in 2007–2009 was 54/million popula-
tion aged ,20 years. Four sub-districts had an annual
incidence .100/million population aged ,20 years, the
highest rates ever reported. Young PNG children do not
respond well to measles vaccine. Because of this, efforts
such as supplementary measles immunisation programs
should continue in order to reduce the pool of non-
immune older people surrounding the youngest and most
vulnerable members of PNG communities.
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4+, with levels of $1+ regarded as positive. This test was
performed in an accredited laboratory and had been assessed and
approved by the Australian National Association of Testing
Authorities in accordance with requirements of the Australian
National Pathology Accreditation Advisory Council. Details of
other laboratory tests including malaria microscopy, plasma
biochemistry and bacterial culture have been published elsewhere
[20].
Case definition of SSPE
Confirmed SSPE was defined as clinical features of SSPE and
the presence of measles-specific IgG in CSF, regardless of titer.
Probable SSPE was defined as clinical features of SSPE and
negative measles-specific IgG in CSF or when no LP was
performed.
Data analysis
The calculation of SSPE incidence was based on PNG Census
data for the year 2000 [8] which includes population structure at
provincial, district and local-level government (LLG, sub-district)
level. The 2008 population was estimated by applying an annual
growth rate of 2.6% (Dr Bryant Allen, Australian National
University, Canberra, Australia; personal communication). Using
this approach, the total population for Madang Province was
estimated to be 448,330 with 241,165 (53.8%) ,20 years of age.
The Global Positioning System co-ordinates of each child’s home
village were obtained to facilitate LLG incidence estimates [21].
All SSPE incidence rates were expressed per million population
,20 years of age which ranged from 5,545 in Iabu Rural LLG to
28,066 in Amenob Rural LLG with an inter-quartile range of
9,880 to 21,267. Reported annual rates of measles vaccination
coverage [11,12] and cases of acute measles infection reported to
the PNG Department of Health [12,13] were obtained from
World Health Organization sources. Statistical testing was by
means of parametric or non-parametric tests using PASW
Statistics (version 17; SPSS Inc. Chicago, Ill) and a level of
significance of 0.05.
Results
Presenting features and clinical course
Baseline, clinical and laboratory data relating to cases of SSPE
identified during the 19-month surveillance period are summa-
rized in Table 1. These 22 children (16 confirmed and 6 probable
cases; see below) were a subset of 671 admitted with severe illness
during the study period. Although the median duration of illness
prior to admission reported by the parent(s)/guardian(s) was 60
(range 1 to 1,000) days, the data provided were not sufficient to
allow an accurate estimate of the age of each child at symptom
onset.
Two children had documentation or parental knowledge of a
past history of acute measles infection, one at six months and the
other at two years of age. Neither had a documented history of
measles vaccination. There were 14 (64%) children in whom the
Figure 1. Papua New Guinean national vaccine coverage from 1997 to 2008.
doi:10.1371/journal.pntd.0000932.g001
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these (59%) had subsequently received the second dose. In a
contemporaneous sample of 44 children hospitalized with other
severe non-SSPE illness matched 2:1 by age and sex with the
SSPE cases, the equivalent percentages were 67% and 67%
respectively (P.0.55 by Chi-squared test). Two children diagnosed
with SSPE within a few months of each other were first cousins.
Sixteen children had characteristic myoclonic jerks on admis-
sion and four had a clear prior history of myoclonic jerks obtained
from the child’s parents. One child presented with a short (two-
week) history of severe involuntary muscle spasms and died soon
after admission, while another presented with complex involuntary
dyskinetic movements of upper and lower limbs. The majority of
children had additional neurologic findings such as impaired
consciousness, difficulty walking and impairment of speech.
LP was performed in 18 of the 22 children. Sixteen of these
(89%), including the two with atypical non-myoclonic features,
had high titre measles-specific antibodies in both serum and CSF
and were therefore confirmed cases of SSPE. Of the probable
cases, four did not undergo LP but each had high serum titres of
measles-specific antibodies. The remaining two children presented
with clinical features consistent with SSPE (myoclonus, motor and
speech deficits) with negative CSF measles IgG titers but elevated
serum titres at 1:2048 and 1:16, respectively. The latter child had
no history of measles vaccination.
In all six probable SSPE cases, no other cause of encephalop-
athy was identified. Normal plasma electrolytes and hepatorenal
function excluded metabolic, renal and hepatic encephalopathy.
Giemsa-stained thick blood films were negative for malaria
parasites and plasma C-reactive protein, blood lactate, white cell
count and blood culture results did not suggest an acute infective
aetiology. The absence of a CSF pleocytosis in the two children
with probable SSPE in whom LP was performed made
tuberculous meningitis or cryptococcal meningitis unlikely. CSF
from both children was negative by PCR for enteroviruses,
Japanese encephalitis virus, Murray Valley encephalitis virus, West
Nile virus (including Kunjin) and dengue virus, and serum was
negative for the presence of IgM to flaviviruses. Based on clinical
presentation and course, serum measles antibody titres and the
exclusion of other causes of an encephalopathy, the six children
with probable SSPE were included in estimates of SSPE incidence.
Although only one child died in hospital, the remaining children
were discharged in line with usual management of SSPE in PNG.
These children had moderate or severe disability requiring
assistance with most or all activities of daily living. An examination
of post-discharge outcome was beyond the scope of the present
study.
Incidence of SSPE in relation to national vaccine
coverage and acute measles incidence
Figures 1 and 2 show PNG national vaccine coverage and acute
measles cases since 1997 [11,12,13], and the year of birth of the
present 22 SSPE cases is shown in Figure 3. Despite relatively
stable vaccination coverage between 50% and 65% from 1997 to
2008, there was a substantial increase in the numbers of reported
acute measles cases in 2002 with a smaller prior peak in 1999 and
Figure 2. Annual reported numbers of cases of acute measles infection in Papua New Guinea from 1997 to 2008.
doi:10.1371/journal.pntd.0000932.g002
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years of birth of the SSPE cases and that for acute measles
nationally (Spearman r=0.88, P=0.002).
Provincial and district incidence of SSPE
The location of the home village for each child with SSPE and
the annual incidence of SSPE in the 13 districts in Madang
Province are shown in Figure 4. The majority of the children were
from remote rural districts with very limited health care access.
The overall estimated annual incidence for Madang province was
29 (95% confidence intervals [18 to 45])/million total population
or 54/million population ,20 years of age. In Josephstaal, Yawar,
Astrolabe Bay and Bundi LLGs, the estimated annual incidence
was 296 [96 to 691], 194 [78 to 400], 122 [15 to 442] and 119 [3
to 660]/million, respectively. There were no reported SSPE cases
from 4 districts. Three of these have no roads and are only
accessible by air, river or foot.
Discussion
The present study conducted in coastal Madang Province
confirms the relatively high incidence of SSPE in PNG shown
previously in several highland provincial surveys conducted during
the 12 years up to 1999 [5,6,22]. However, our data also show that
such incidence rates must be interpreted in the light of prior
measles epidemiology. There was a clear association between the
year of birth of our SSPE cases and national figures for acute
measles infection that included a substantial increase in cases in
the year 2002. This relationship suggests that, despite the
possibility of under-reporting [10,14,15], temporal trends in
measles cases in PNG are relatively accurate. Without equivalent
antecedent data, it is difficult to interpret prior reports [5,6,22] in
which a high SSPE incidence may have simply reflected peaks in
measles cases 3–10 years beforehand. The decline in reported
acute measles in PNG since 2002, including very few cases over
the last 5 years [13], should herald a substantial reduction in SSPE
incidence in PNG over the next few years. Nevertheless, a rising
seroprevalence during childhood which exceeds that associated
with vaccination coverage and SIA may mean that continued local
measles transmission will sustain future low-level presentation of
new cases [10]. Although our study captured the delayed peak in
SSPE incidence attributable to the 2002 measles epidemic, there
have been two further children admitted to Modilon Hospital with
a clinical diagnosis of SSPE in the 12 months since recruitment to
the present study finished.
The demographic features and clinical course of our patients
were similar to those of published series from PNG and other
countries. Consistent with previously-reported studies [23], we
could not always determine age of onset of symptoms accurately,
but the median age at the time of admission in our children (7.3
years) and the male:female ratio (1.4:1) were similar to those in
SSPE cases from the PNG highlands a decade ago (7.9 years and
1.2:1, respectively) [4]. Although a male excess is usual, there has
been a large age range at presentation, from ,5 years in one of the
first PNG studies [22] to .10 years in Europid populations
[23,24]. This is likely to reflect population-specific differences in
contributing factors such as persistence of maternal antibodies and
vaccination policies.
The present study is the first to have had access to LLG
population data to facilitate an assessment of SSPE epidemiology
at a sub-provincial level in PNG. The incidence of SSPE exceeded
100 per million population ,20 years old in four LLGs of Madang
Province. Although there were relatively few cases in some of sub-
districts, this is the highest rate yet recorded. Only half of PNG
children receive both doses of measles vaccine before their first
birthday [10,13], but the prior measles vaccination rate docu-
mented for the children from these districts did not differ
significantly from that of the non-SSPE severely ill control
children nor from national coverage at the time of likely measles
infection. This suggests that factors other than vaccine delivery
were responsible. There are known continuing difficulties with
ensuring a reliable vaccine cold chain in PNG [25,26], but it is also
possible that post-measles vaccination seroconversion rates were
unusually low in these areas or that the acute measles incidence
was particularly high. Alternatively, the children in these
communities have an increased susceptibility to SSPE.
Vaccine seroconversion is highly age-dependent. Only 36% of
Melanesian children will develop protective measles immunity
after their first vaccination at 6 months [27] while recent data from
Madang also indicate low rates of protective immunity to measles
in children who had received one or both doses of measles vaccine
before one year of age [10]. This reflects, in part, persistence of
low-level interfering passive maternal antibodies for up to 12
months [28], especially when maternal immunity has been
acquired by natural infection rather than vaccination [29]. The
weight of epidemiologic evidence suggests that SSPE is more likely
to occur when measles infects a child in the first year of life
[23,30,31]. Indeed, the clear relationship between year of birth of
our children with SSPE and nationally reported measles incidence
implies that our cases were very young when they encountered
measles virus for the first time. Given that most young children are
vulnerable to measles, even if vaccinated, it is likely that differences
in the numbers of SSPE cases between districts reflect similar local
differences in acute measles incidence between 1998 and 2003.
Table 1. Baseline, clinical and laboratory data of the 22 SSPE
cases at time of hospital admission.
Demographic details:
Age (months) 87 (76–95)
Male sex (%) 59
History of measles (%) 9
At least one measles vaccination (%) 59
Clinical signs:
Malnutrition (%) 16
Temperature (uC) 36.9 (36.4–37.5)
Blantyre Coma Score #4( % ) 5 5
Myoclonic jerks (%) 72
Upper motor neurone signs (%) 72
Abnormal speech (%) 86
Laboratory results:
Lumbar puncture performed (%) 82
CSF white cells (/mL) 0 [0–20]*
CSF protein (g/L) 0 [0–3.0]*
Serum measles antibody titre 12,228 [16–32,768]
CSF measles antibody titre 128 [0–512]*
Outcome at time of hospital discharge:
Died (%) 5
Severe disability (%) 72
*in the 18 who underwent lumbar puncture.
Data are percentage, mean and (95% confidence intervals), or median and
[range].
doi:10.1371/journal.pntd.0000932.t001
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achieve 92–95% vaccination coverage that includes two separate
doses of the vaccine [32]. Given that the expanded programme for
immunisation started in 1982 in PNG and the fact that measles
vaccine coverage in PNG has remained #70% for at least the last
10 years [11], it is likely that herd immunity was very low in the
more remote communities of Madang Province early in the
millennium and that acute measles cases were correspondingly
high. The fact that four very remote districts were not represented
in our series suggests that either they were isolated from the
increase in acute measles cases at that time or that children with
SSPE were not brought to Modilon Hospital because of the logistic
issues involved with patient transfer.
Prior to widespread vaccination, the incidence of SSPE was
between 1.2–6.7 per million population ,20 years of age in
countries where valid data were available [33,34,35,36]. However,
incidence rates up to 43 per million population ,20 years of age
have been estimated in some developing countries [6]. Further-
more, even within closely located communities, the incidence of
SSPE is not uniform. For example, Ashkenazi Jews in Israel have a
lower rate of SSPE than Separdic Jews (0.5 vs 3.4 cases per million
population, respectively) [36]. Our children are from a compar-
atively homogenous Melanesian group but there were two first
cousins of similar age diagnosed within a year of one another.
Although from a single set of close-living relatives, SSPE has been
described previously in sibling and twin pairs implying at least
some familial predisposition, but a clear genetic basis for
susceptibility has yet to be defined [37,38,39,40,41]. Single
nucleotide polymorphisms in a number of immunity-related genes
have been found to be associated with SSPE in Japanese [42,43]
and Turkish [44] patients, but not in other ethnic groups [45]. The
search for genetic associations is difficult in an uncommon disease
like SSPE, even in high incidence settings such as PNG, and they
would have to account for socio-cultural factors that might
promote measles infection at an early age in relatively non-
immune, unvaccinated populations [46].
SSPE is diagnosed on clinical grounds alone in resource poor,
high incidence settings similar to that of the present study where
there are no brain imaging or EEG facilities. Serologic testing for
measles is only available as a research or epidemiologic tool. In our
case series, six children had probable SSPE without confirmatory
CSF serology. Four of these children did not have LP performed
but had very high serum titres of measles-specific IgG. The
remaining two had negative CSF serology but characteristic
clinical features. Because relatively comprehensive clinical and
laboratory investigations excluded other likely causes of enceph-
alopathy, the fact that measles CSF and serum titres in SSPE cases
can overlap those of controls [3], and given the high pre-test
probability of SSPE, we believe that these two latter children
represent part of the spectrum of the disease. Our series also
Figure 3. Year of birth of the 22 children with subacute sclerosing panencephalitis (SSPE).
doi:10.1371/journal.pntd.0000932.g003
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presented with muscle spasms and rapidly progressed to death
within two weeks of illness onset. The other had a subacute history
and complex dyskinetic movements. Atypical presentations have
been described previously and are sometimes accompanied by
radiologic evidence of extensive brainstem as well as cortical
involvement [47]. It is likely that, had cerebral imaging been
available, there would have been similar radiologic findings in
these two children.
The PNG Pediatric Guidelines recommend that the first
measles vaccine be given at 6 months of age and the second at
9 months of age [7]. The reason for this policy is the increased
morbidity and mortality from acute measles in younger infants
rather than high rates of SSPE [48]. However, the low
seroconversion rates in this age-group argue for a delay in the
age of the first measles vaccine to 9 months of age followed by a
second dose at 12–15 months. This could be reconsidered if there
were to be an outbreak of measles, but this has not happened in
PNG for the last 8 years.
The present study extends past published data suggesting that
PNG has the highest reported incidence of SSPE globally.
However, this high incidence is related to prior measles epidemics.
We have also shown that the incidence of SSPE varies between
communities. This could reflect localized failure of the vaccine
cold chain, community-specific factors that increase measles
transmission, variability in public health surveillance and/or
differences in genetic susceptibility to SSPE. Young PNG children
do not respond well to measles vaccine. Because of this, efforts
such as SIA should continue in order to reduce the pool of non-
immune older people surrounding the youngest and most
vulnerable members of PNG communities. SSPE has a high
mortality, but most children with SSPE require prolonged care
because of profound disabilities. Such dependence comes at
substantial cost for caregivers.
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